Axial Spondyloarthritis (axSpA) Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | UCB Biopharma, Celgene, Novartis, Pfizer, Merck, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lil

DelveInsight's "Axial Spondyloarthritis (axSpA) Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Axial Spondyloarthritis (axSpA), historical and forecasted epidemiology as well as the Axial Spondyloarthritis (axSpA) market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Axial Spondyloarthritis (axSpA) market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Axial Spondyloarthritis (axSpA) Market Forecast
https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Axial Spondyloarthritis (axSpA) Market Report:
• The Axial Spondyloarthritis (axSpA) market size was valued approximately USD 5,590 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• A total of 3,981,346 individuals in the 7MM were overall prevalent for axSpA. Throughout the prediction period (from 2022 to 2032), it is expected that these cases will rise
• In June 2023, UCB, a leading global biopharmaceutical firm, announced today that the European Commission (EC) has granted marketing authorization for BIMZELX® (bimekizumab). This authorization extends to the treatment of adults with active psoriatic arthritis (PsA) and adults with active axial spondyloarthritis (axSpA), including non-radiographic axSpA (nr-axSpA) and ankylosing spondylitis (AS), commonly referred to as radiographic axSpA. These approvals mark the first authorizations for bimekizumab in PsA and axSpA worldwide and the second and third indications for bimekizumab in the EU.
• The US reported the highest number of axSpA cases in 2021, totaling 2,217,315 cases, while the EU5 countries reported 1,751,778 cases during the same period
• Japan had the fewest diagnosed prevalent instances of axSpA (7MM) in 2021 with 5,000 cases
• Due to its benign history, ankylosing spondylitis is almost never detected in the US in about 50% of patients. In the US, the time between the development of symptoms and the diagnosis of ankylosing spondylitis has been estimated to be around 13 years
• Key Axial Spondyloarthritis (axSpA) Companies: UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lilly and Company, Merck Sharp & Dohme LLC, Pfizer, Novartis, Jiangsu HengRui Medicine, UCB Biopharma, and others
• Key Axial Spondyloarthritis (axSpA) Therapies: Bimekizumab, CC-99677, ABY- 035, Filgotinib, KHK4827, Ixekizumab, Golimumab, etanercept, Secukinumab, SHR0302, Certolizumab Pegol, and others
• The Axial Spondyloarthritis (axSpA) epidemiology based on gender analyzed that the prevalent population of Axial Spondyloarthritis showed a male predominance, whereas, nr-axSpA showed female predominance.
• The Axial Spondyloarthritis (axSpA) market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Axial Spondyloarthritis (axSpA) pipeline products will significantly revolutionize the Axial Spondyloarthritis (axSpA) market dynamics.

Axial Spondyloarthritis (axSpA) Overview
Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) are two subtypes of the chronic, immune-mediated, inflammatory illness known as axial spondyloarthritis (axSpA).

Get a Free sample for the Axial Spondyloarthritis (axSpA) Market Report
https://www.delveinsight.com/report-store/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Axial Spondyloarthritis (axSpA) Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Axial Spondyloarthritis (axSpA) Epidemiology Segmentation:
The Axial Spondyloarthritis (axSpA) market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Axial Spondyloarthritis (axSpA)
• Prevalent Cases of Axial Spondyloarthritis (axSpA) by severity
• Gender-specific Prevalence of Axial Spondyloarthritis (axSpA)
• Diagnosed Cases of Episodic and Chronic Axial Spondyloarthritis (axSpA)

Download the report to understand which factors are driving Axial Spondyloarthritis (axSpA) epidemiology trends @ Axial Spondyloarthritis (axSpA) Epidemiology Forecast
https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Axial Spondyloarthritis (axSpA) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Axial Spondyloarthritis (axSpA) market or expected to get launched during the study period. The analysis covers Axial Spondyloarthritis (axSpA) market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Axial Spondyloarthritis (axSpA) Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Axial Spondyloarthritis (axSpA) Therapies and Key Companies
• Bimekizumab: UCB Biopharma
• CC-99677: Celgene
• ABY- 035: Inmagene Biopharmaceuticals
• Filgotinib: Galapagos NV
• KHK4827: Kyowa Kirin Co., Ltd.
• Ixekizumab: Eli Lilly and Company
• Golimumab: Merck Sharp & Dohme LLC
• etanercept: Pfizer
• Bimekizumab: UCB Biopharma
• Secukinumab: Novartis
• SHR0302: Jiangsu HengRui Medicine
• Certolizumab Pegol: UCB Biopharma

Discover more about therapies set to grab major Axial Spondyloarthritis (axSpA) market share @ Axial Spondyloarthritis (axSpA) Treatment Market
https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Axial Spondyloarthritis (axSpA) Market Drivers
• The introduction of novel products
• Increasing prevalence
• Awareness about the Disease
• Research and development strategies

Axial Spondyloarthritis (axSpA) Market Barriers
• High-cost treatment
• Delay in Diagnosis
• Immunogenicity
• Loss of patent exclusivity
• Availability of generics
• Poor Quality of Life

Scope of the Axial Spondyloarthritis (axSpA) Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Axial Spondyloarthritis (axSpA) Companies: UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lilly and Company, Merck Sharp & Dohme LLC, Pfizer, Novartis, Jiangsu HengRui Medicine, UCB Biopharma, and others
• Key Axial Spondyloarthritis (axSpA) Therapies: Bimekizumab, CC-99677, ABY- 035, Filgotinib, KHK4827, Ixekizumab, Golimumab, etanercept, Secukinumab, SHR0302, Certolizumab Pegol, and others
• Axial Spondyloarthritis (axSpA) Therapeutic Assessment: Axial Spondyloarthritis (axSpA) current marketed and Axial Spondyloarthritis (axSpA) emerging therapies
• Axial Spondyloarthritis (axSpA) Market Dynamics: Axial Spondyloarthritis (axSpA) market drivers and Axial Spondyloarthritis (axSpA) market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Axial Spondyloarthritis (axSpA) Unmet Needs, KOL's views, Analyst's views, Axial Spondyloarthritis (axSpA) Market Access and Reimbursement

To know more about Axial Spondyloarthritis (axSpA) companies working in the treatment market, visit @ Axial Spondyloarthritis (axSpA) Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Axial Spondyloarthritis (axSpA) Market Report Introduction
2. Executive Summary for Axial Spondyloarthritis (axSpA)
3. SWOT analysis of Axial Spondyloarthritis (axSpA)
4. Axial Spondyloarthritis (axSpA) Patient Share (%) Overview at a Glance
5. Axial Spondyloarthritis (axSpA) Market Overview at a Glance
6. Axial Spondyloarthritis (axSpA) Disease Background and Overview
7. Axial Spondyloarthritis (axSpA) Epidemiology and Patient Population
8. Country-Specific Patient Population of Axial Spondyloarthritis (axSpA)
9. Axial Spondyloarthritis (axSpA) Current Treatment and Medical Practices
10. Axial Spondyloarthritis (axSpA) Unmet Needs
11. Axial Spondyloarthritis (axSpA) Emerging Therapies
12. Axial Spondyloarthritis (axSpA) Market Outlook
13. Country-Wise Axial Spondyloarthritis (axSpA) Market Analysis (2019-2032)
14. Axial Spondyloarthritis (axSpA) Market Access and Reimbursement of Therapies
15. Axial Spondyloarthritis (axSpA) Market Drivers
16. Axial Spondyloarthritis (axSpA) Market Barriers
17. Axial Spondyloarthritis (axSpA) Appendix
18. Axial Spondyloarthritis (axSpA) Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Axial Spondyloarthritis (axSpA) Pipeline https://www.delveinsight.com/report-store/axial-spondyloarthritis-axspa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Axial Spondyloarthritis (axSpA) Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Axial Spondyloarthritis (axSpA) market. A detailed picture of the Axial Spondyloarthritis (axSpA) pipeline landscape is provided, which includes the disease overview and Axial Spondyloarthritis (axSpA) treatment guidelines.

Axial Spondyloarthritis (axSpA) Epidemiology
https://www.delveinsight.com/report-store/axial-spondyloarthritis-axspa-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Axial Spondyloarthritis (axSpA) Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Axial Spondyloarthritis (axSpA) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Insulin Glargine Biosimilar http://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight
DelveInsight's, "Insulin Glargine Biosimilar Insight, 2024," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Insulin Glargine Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cell And Gene Therapy For Multiple Myeloma m Market http://www.delveinsight.com/report-store/cell-and-gene-therapy-for-multiple-myeloma-market
DelveInsight's "Cell And Gene Therapy For Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cell And Gene Therapy For Multiple Myeloma, historical and forecasted epidemiology as well as the Cell And Gene Therapy For Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

End Stage Renal Disease Market http://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market
DelveInsight's "End-Stage Renal Disease (ESRD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fenebrutinib Market http://www.delveinsight.com/report-store/fenebrutinib-emerging-insight-and-market-forecast
"FENEBRUTINIB- Market Size, Forecast, and Emerging Insight - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the FENEBRUTINIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

Bcl-2 Inhibitors Market http://www.delveinsight.com/report-store/bcl2-inhibitors-market-forecast
DelveInsight's "BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of BCL-2 Inhibitors, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Bispecifics Market http://www.delveinsight.com/report-store/bispecifics-market-forecast
DelveInsight's "Bispecifics Market Size, Target Population, Competitive Landscape and Market Forecast - 2034" report delivers an in-depth understanding of Bispecifics, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.